Celldex Therapeutics, Inc. (NASDAQ:CLDX)

CAPS Rating: 3 out of 5

A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease.

Recs

0
Player Avatar TheStreetOutside (< 20) Submitted: 7/16/2010 7:25:52 PM : Outperform Start Price: $4.51 CLDX Score: -15.28

Extremely undervalued pipeline with gamechanging technology...biotech value at its best!

Report this Post 2 Comments
Member Avatar TheStreetOutside (< 20) Submitted: 8/4/2010 5:48:39 PM
Recs: 0

Today´s conference call http://tinyurl.com/2c5dw46

Member Avatar TheStreetOutside (< 20) Submitted: 8/7/2010 6:30:47 PM
Recs: 0

Not mine, but good look at current clinical trials show just how undervalued this is... http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/threadview?m=te&bn=78350&tid=25162&mid=25162&tof=10&frt=1#25162

Featured Broker Partners


Advertisement